3 results
Approved WMOCompleted
Primary:• To evaluate the ability of relugolix to achieve and maintain serum testosterone suppression to castrate levels (<= 50 ng/dL [1.7 nmol/L]) in men with androgen-sensitive advanced prostate cancer.Secondary:• To evaluate the time…
Approved WMOCompleted
To test the first feasibility and safety of intratumoral 166-holmium microspheres implantation in pancreatic cancer in a controlled, open-surgery setting.
Approved WMORecruiting
We hypothesize that a significant proportion of the patients will benefit more from focal therapy as compared to usual care in terms of morbidity and quality of life, without compromising oncological effectiveness. Primary objective: To study the…